AIMS Presents the Latest on Multiple Sclerosis Treatments Educational Programs for Healthcare Professionals Includes Live Events & [...]
Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis Friday, August 15, 2014 [...]
PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis Wednesday, July 23, 2014 [...]
Teva files Citizen Petition with the U.S. Food and Drug Administration (FDA) regarding the Complexity of COPAXONE® (Glatiramer Acetate) [...]
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis Monday, June 30, 2014 8:00 am EDT CAMBRIDGE, [...]
Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple [...]
Genzyme’s Lemtrada Resubmission Accepted for Review by FDA - Agency action expected in Q4 2014 - Cambridge, Mass. - May 30, 2014 - [...]
Data from Biogen Idec’s Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses Friday, May 30, 2014 [...]
Biogen Idec Announces Official Partnership with Sailing Sclerosis Oceans of Hope to Globally Change Perceptions of MS Wednesday, May [...]
EMD Serono Data at CMSC & ACTRIMS Annual Meeting Reinforces Proven Efficacy of Rebif® (interferon beta-1a) and Demonstrates Continued [...]